Plasma L-Arginine levels
assessed by ELISA predict response of cancer patients
to immune checkpoint
New highlight in Annals of Oncology!
the era of immuno-oncology, identification of reliable predictive biomarkers -
that can help for a better selection of cancer patients who might respond
Checkpoint Blockers (ICB)
- remains crucial. Expression of PD-L1 on cancer cells, high micro satellite
instability, and tumor mutational burden are, to date, the only predictors of
ICB response while still being imperfect (1). Even though tumor tissue
profiling is key for biomarker
insights from the periphery are needed in order to allow an easy-to-implement
is known to play a key role in shaping the immune response. Amino Acid
degradation by tumor and/or suppressive immune cells has been shown to limit
anti-tumor immune response (2, 3). In a recent study - supervised by Antoine Italiano and conducted in
collaboration between teams from Explicyte (Bordeaux, France), Institut Bergonié (Bordeaux, France),
and Institut Gustave Roussy (Villejuif, France), and
published in Annals of Oncology (4) - plasmatic level of
L-Arginine (Arg) has been found to be associated with clinical outcome of
advanced cancer patients treated with ICB. Using an ELISA approach for Arg
quantification (#IS-I-0400R) applied on two independent
cohorts, Peyraud et al. demonstrated that low
plasmatic level of Arg was associated with a worse clinical outcome.
a new product on the market, our novel ELISA kit for Arg quantification (#IS-I-0400R) requires as little as 20µL
plasma sample volume and therefore offers a valuable and easy approach to
predicting sensitivity of patients to ICB before treatment onset.
(주)엘바이오시스템은 immusmol의 한국공식대리점입니다.
제품의 주문 및 관련정보가 필요하시면 이메일로 문의해 주세요.